<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Kazan medical journal</journal-id><journal-title-group><journal-title xml:lang="en">Kazan medical journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Казанский медицинский журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0368-4814</issn><issn publication-format="electronic">2587-9359</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2913</article-id><article-id pub-id-type="doi">10.17750/KMJ2016-262</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Possibilities of positron emission tomography in the metastatic breast cancer diagnosis</article-title><trans-title-group xml:lang="ru"><trans-title>Возможности позитронно-эмиссионной томографии в диагностике метастатического рака молочной железы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ramazanova</surname><given-names>M S</given-names></name><name xml:lang="ru"><surname>Рамазанова</surname><given-names>Мадина Султановна</given-names></name></name-alternatives><email>ramazanovam@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kislichko</surname><given-names>A G</given-names></name><name xml:lang="ru"><surname>Кисличко</surname><given-names>Анатолий Григорьевич</given-names></name></name-alternatives><email>ramazanovam@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Glushkov</surname><given-names>E A</given-names></name><name xml:lang="ru"><surname>Глушков</surname><given-names>Евгений Александрович</given-names></name></name-alternatives><email>ramazanovam@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kirov State Medical Academy</institution></aff><aff><institution xml:lang="ru">Кировская государственная медицинская академия</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2016</year></pub-date><volume>97</volume><issue>2</issue><issue-title xml:lang="en">VOL 97, NO2 (2016)</issue-title><issue-title xml:lang="ru">ТОМ 97, №2 (2016)</issue-title><fpage>262</fpage><lpage>267</lpage><history><date date-type="received" iso-8601-date="2016-05-13"><day>13</day><month>05</month><year>2016</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Ramazanova M.S., Kislichko A.G., Glushkov E.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, Рамазанова М.С., Кисличко А.Г., Глушков Е.А.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Ramazanova M.S., Kislichko A.G., Glushkov E.A.</copyright-holder><copyright-holder xml:lang="ru">Рамазанова М.С., Кисличко А.Г., Глушков Е.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://kazanmedjournal.ru/kazanmedj/article/view/2913">https://kazanmedjournal.ru/kazanmedj/article/view/2913</self-uri><abstract xml:lang="en"><p>An analysis of published data on the possibilities of the positron emission tomography method application in complex diagnostic and treatment activities in metastatic breast cancer was performed. The possibilities are described and the method characteristics according to series of studies, in particular with regard to the various localization metastases identification are given. It is noted that, compared with conventional imaging techniques, positron emission tomography is more sensitive and specific method of distant metastases diagnosis. The results of clinical studies on assessment of the method application possibilities in the detection of breast cancer metastases in lymph nodes, various organs and bone metastases are given. It has been shown that the introduction of sodium fluoride into practice allowed to use this agent as bone tissue biomarker, which can be used in positron emission tomography performing. The data that the simultaneous use of positron emission tomography with 18F-fluorodeoxyglucose and computed tomography has a high diagnostic value in relation to the breast cancer distant metastases detection are presented. The method possibilities for the various forms of primary invasive breast cancer identification, including invasive ductal and lobular cancer are considered. The prospects analysis for a further increase of opportunities for positron emission tomography application is performed, in particular, reports on the possibility of so-called hybrid scanning using positron emission tomography and magnetic resonance imaging are considered. It is highlighted that the most important aim of the method use in clinical practice in the prospect may be local-regional recurrence and distant metastasis monitoring after primary treatment for breast cancer.</p></abstract><trans-abstract xml:lang="ru"><p>Выполнен анализ литературных данных о возможностях применения метода позитронно-эмиссионной томографии в комплексе лечебно-диагностических мероприятий при метастатическом раке молочной железы. Описаны возможности и приведены характеристики метода по данным ряда исследований, в частности в отношении выявления метастазов различной локализации. Указано, что по сравнению с обычными методами визуализации позитронно-эмиссионная томография служит более чувствительным и специфичным методом диагностики отдалённых метастазов. Приведены результаты клинических исследований по оценке возможностей применения метода в выявлении метастазов рака молочной железы в лимфатических узлах, различных органах, а также костных метастазов. Показано, что внедрение в практику натрия фторида позволило применять этот препарат как биомаркёр костной ткани, который может быть использован при выполнении позитронно-эмиссионной томографии. Приведены данные о том, что одновременное применение позитронно-эмиссионной томографии с 18F-фтордезоксиглюкозой и компьютерной томографии обладает высокой диагностической ценностью в отношении выявления отдалённых метастазов при раке молочной железы. Рассмотрены возможности метода по выявлению различных форм первичного инвазивного рака молочной железы, в том числе инвазивного протокового и долькового рака. Выполнен анализ перспектив дальнейшего увеличения возможностей применения позитронно-эмиссионной томографии, в частности рассмотрены сообщения о возможности так называемого гибридного сканирования с помощью позитронно-эмиссионной томографии и магнитно-резонансной томографии. Подчёркнуто, что важнейшей задачей использования метода в клинической практике в перспективе может стать мониторирование местно-регионарных рецидивов и отдалённых метастазов после первичного лечения рака молочной железы.</p></trans-abstract><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>positron emission tomography</kwd><kwd>metastasis</kwd><kwd>bone scintigraphy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>позитронно-эмиссионная томография</kwd><kwd>метастазы</kwd><kwd>сцинтиграфия костей скелета</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Abe K., Sasaki M., Kuwabara Y. et at. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann. Nucl. Med. 2005; 19: 573-579. http://dx.doi.org/10.1007/BF02985050</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Аukеtа T.S., Straver M.E., Peelers M.J. et al. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur. J. Cancer. 2010; 46: 3205-3210. http://dx.doi.org/10.1016/j.ejca.2010.07.034</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Avril N., Dose J., Janicke F. et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J. Clin. Oncol. 1996; 14: 1848-1857.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Callowitsch H.J., Kresnik E., Gasser J. et at. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow up of patients with breast carcinoma: a comparison to conventional imaging. Invest. Radiol. 2003; 38: 250-256. http://dx.doi.org/10.1097/01.RLI.0000063983.86229.f2</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Catalano O.A., Nicolai E., Rosen B.R. et al. Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients. Br. J. Cancer. 2015; 112 (9): 1452-1460. http://dx.doi.org/10.1038/bjc.2015.112</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006; 12 (20): 6243-6249. http://dx.doi.org/10.1158/1078-0432.CCR-06-0931</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Coleman R.E., Gregory W., Marshall H. et al. The metastatic microenvironment of breast cancer: clinical implications. Breast. 2013; 2: 50-56. http://dx.doi.org/10.1016/j.breast.2013.07.010</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Constantinidou A., Martin A., Sharma B., Johnston S.R. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann. Oncol. 2011; 22: 307-314. http://dx.doi.org/10.1093/annonc/mdq343</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Di Gioia D., Stieber P., Schmidt G.P. et al. Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase. Br. J. Cancer. 2015; 112 (5): 809-818. http://dx.doi.org/10.1038/bjc.2015.8</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dong Y., Hou H., Wang C. et al. The diagnostic value of 18F-FDG PET/CT in association with serum tumor marker assays in breast cancer recurrence and metastasis. Biomed Res. Int. 2015; ID 489021. http://dx.doi.org/10.1155/2015/489021. http://dx.doi.org/10.1155/2015/489021</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Door R.K., Muzi M., Peterson L.M. et al. Kinetic analysis of 18E-fluoride PET images of breast cancer bone metastases. J. Nucl. Med. 2010; 51: 521-527. http://dx.doi.org/10.2967/jnumed.109.070052</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ergul N., Kadioglu H., Yildiz S. et al. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy. Acta Radiol. 2014. 56(8). http://dx.doi.org/10.1177/0284185114539786</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Eubank W.B., Mankoff D.A., Takasugi J. et al. 18 fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J. Clin. Oncol. 2001; 19: 3516-3523.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Feriay J., Steliarova-Foucher E., Lortet-Tieulent J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J Cancer. 2013; 49: 1374-1403. http://dx.doi.org/10.1016/j.ejca.2012.12.027</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Fletcher J.W., Djulbegovie B., Soares H.P. et al. Recommendations on the use of 18F-FDG PET in oncology. J. Nucl. Med. 2008; 49: 480-508. http://dx.doi.org/10.2967/jnumed.107.047787</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Fujimoto R., Higashi T., Nakamoto Y. et al. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PEY. Ann. Nucl. Med. 2006; 20: 399-408. http://dx.doi.org/10.1007/BF03027375</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Greco M., Crippa F., Agresti R. et al. Axillary lymph node staging in breast cancer by 2-F1 uoro-2-deoxy-D-giucose-positron emission tomography: Clinical evaluation and alternative management. J. Natl. Cancer Inst. 2001; 93: 630-635. http://dx.doi.org/10.1093/jnci/93.8.630</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Hong S., Li J., Wang S. (18)FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Surg. Oncol. 2013; 22: 139-143. http://dx.doi.org/10.1016/j.suronc.2013.03.001</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Iagaru A., Mima E., Yaghou M.S et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase. J. Nucl. Med. 2009; 50: 501-505. http://dx.doi.org/10.2967/jnumed.108.058339</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Iagaru A., Mima E., Mosci C. et al. Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J. Nucl. Med. 2013; 54: 176-183. http://dx.doi.org/10.2967/jnumed.112.108803</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Isasi C.R., Moadel R.M., Blaufox M.D. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res. Treat. 2005; 90: 105-112. http://dx.doi.org/10.1007/s10549-004-3291-7</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Jambor I., Kuisma A., Ramadan S. et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, (18) F-NaFPET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol. 2016; 55 (1): 1-9. http://dx.doi.org/10.3109/0284186X.2015.1027411</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Manohar K., Mittal B.R., Senthil R. et al. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Nucl. Med. Commun. 2012; 33: 591-596. http://dx.doi.org/10.1097/MNM.0b013e3283516716</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Morris P.G., Lynch C., Feeney J.N. et at. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J. Clin. Oncol. 2010; 28: 3154-3159. http://dx.doi.org/10.1200/JCO.2009.27.5743</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Munoz-Iglesias J., Una-Gorospe J., Allende-Riera A. et al. Unsuspected uterine metastasis of breast carcinoma diagnosed by 18F-FDG PET/CT. Clin. Nucl. Med. 2013; 38 (11): 441-442. http://dx.doi.org/10.1097/RLU.0b013e318292a73b</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>National Cancer Institute. SEER Star Fact Sheets: Breast (Internet). Available at http://seer.cancer.gov/statfacts/htmi/breast.html [cited on Sep. 9, 2013).</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Pan L., Han Y., Sun X. et al. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases; a meta-analysis. J. Cancer Res. Clin. Oncol. 2010; 136: 1007-1022. http://dx.doi.org/10.1007/s00432-009-0746-6</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Peterson J.J., Kransdorf M.J., O’Connor M.I. Diagnosis of occult bone metastases: positron emission tomography. Clin. Relat. Res. 2003; 123: 8120-8128. http://dx.doi.org/10.1097/01.blo.0000093051.96273.7c</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Piccardo A., Altrinetti V., Bacigalupo L. et al. Detection of metastatic bone lesions in breast cancer patients: fused (18)F-Fluoride-PET/MDCT has higher accuracy than MOOT. Preliminary experience. Eur. J. Radiol. 2012; 81: 2632-2638. http://dx.doi.org/10.1016/j.ejrad.2011.12.020</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Port E.R., Yeung H., Gonen M. et al. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann. Surg. Oncol. 2006; 13: 677-684. http://dx.doi.org/10.1245/ASO.2006.03.035</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Riedl C.C., Slobod E., Jochelson M. et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J. Nucl. Med. 2014; 55 (10): 1578-1583. http://dx.doi.org/10.2967/jnumed.114.143297</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Riegger C., Koenlnger A., Hartung V. et al. Comparison of the diagnostic value of FDG- PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients. Acta Radiol. 2012; 53: 1992-1998. http://dx.doi.org/10.1258/ar.2012.110635</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Santiago J.E., Gonen M., Yeung H. et al. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q. J. Nucl. Med. Mol. Imaging. 2006; 50: 61-67.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Tabouret-Viaud C., Botsikas D., Delattre B.M. et al. PET/MR in Breast Cancer. Semin. Nucl. Med. 2015; 45 (4): 304-321. http://dx.doi.org/10.1053/j.semnuclmed.2015.03.003</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Teke F., Teke M., Inal A. et al. Significance of hormone receptor status in comparison of 18F-FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience. Asian. Pac. J. Cancer Prev. 2015; 16 (1): 387-391. http://dx.doi.org/10.7314/APJCP.2015.16.1.387</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Treglia G., Paone G., Ceriani L., Giovanella L. Metastatic brachial plexopathy from breast cancer detected by 18F-FDG PET/MRI. Rev. Esp. Med. Nucl. Imagen. Mol. 2014; 33 (1): 54-55. http://dx.doi.org/10.1016/j.remn.2013.06.007</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Van der Hoeven J.J., Krak N.C., Hoekstra O.S. et al. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J. Clin. Oncol. 2004; 22: 1253-1259. http://dx.doi.org/10.1200/JCO.2004.07.058</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Van Kruchten M., Glaudemans A.W., de Vries E.F. et al. Positron emission tomography of tumour [18F] fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. Eur. J. Nucl. Med. Mol. Imaging. 2015; 42 (11): 1674-1681. http://dx.doi.org/10.1007/s00259-015-3107-5</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Veit-Haibach P., Antoch G., Beyer T. et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br. J. Radiol. 2007; 80: 508-515. http://dx.doi.org/10.1259/bjr/17395663</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Veronesi U., Paganelli G., Galimberti V. et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997; 349: 1864-1867. http://dx.doi.org/10.1016/S0140-6736(97)01004-0</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Wahl R.L., Siegel B.A., Coleman R.E., Catsonis C.G. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J. Clin. Oncol. 2004; 22: 277-285. http://dx.doi.org/10.1200/JCO.2004.04.148</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>You S., Kang D.K., Jung Y.S. et al. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and (18) F-FDG PET/CT. Br. J. Radiol. 2015. DOI: 10.1259/bjr.20150143. http://dx.doi.org/10.1259/bjr.20150143</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Zhang X., Wu F., Han P. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited. Hell. J. Nucl. Med. 2014; 17 (3): 177-183.</mixed-citation></ref></ref-list></back></article>
